← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Rgenix, Inc.
New York, NY
$1,838,914
Total funding
2
Grants
Funding over time
peak $1.1M · FY2014–17$2M$1.5M$1M$500K$0
'14
'15
'16
'17
Funding mix
By agency
NIH$1,838,914 · 2
By mechanism
R44$1,639,260 · 1
R43$199,654 · 1
Investigators at Rgenix, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of an LXR agonist as first in class therapy for treatment of metastatic melanoma$1,117,983
R44 · FY2016 · CA
Development of an LXR agonist as first in class therapy for treatment of metastatic melanoma$521,277
R44 · FY2017 · CA
A microRNA based prognostic service that predicts melanoma metastasis likelihood$199,654
R43 · FY2014 · CA